Navigation Links
New biomarker highly promising for predicting breast cancer outcomes
Date:8/25/2014

A protein named p66ShcA shows promise as a biomarker to identify breast cancers with poor prognoses, according to research published ahead of print in the journal Molecular and Cellular Biology.

Cancer is deadly in large part due to its ability to metastasize, to travel from one organ or tissue type to another and malignantly sprout anew. The vast majority of cancer deaths are associated with metastasis.

In breast cancer, a process called "epithelial to mesenchymal transition" aids metastasis. Epithelial cells line surfaces which come into contact with the environment, such as skin and the gastrointestinal tract. Mesenchymal cells are a type of cell in embryonic tissue and in connective tissue, where they form very loose contacts with one-another. Tumor cells lose mature epithelial characteristics, such as the ability to adhere to their neighbors, and gain those of the mesenchymal cells which enable them to move easily through the cellular matrix and into the blood stream. That enables their metastatic migration to distant organs and tissues.

In this study the researchers, led by Josie Ursini-Siegel of McGill University, show that the protein p66ShcA is highly enriched in breast cancers that have undergone epithelial to mesenchymal transition.

"We showed that elevated p66ShcA expression levels are strongly associated with expression of numerous epithelial to mesenchymal transition genes in all breast cancer subtypes," says Ursini-Siegel. "Thus, p66ShcA may serve as one of the first prognostic biomarkers to identify poor outcome breasts cancers regardless of their molecular subtype."

The ability to predict prognosis is critical to management of treatment. A patient with a good prognosis can be spared aggressive treatment, with its oft-unpleasant side effects. But failure to apply aggressive treatment to an aggressive tumor can lead to death.

Breast cancers stratify into at least five subtypes, each of which is associated with a different outcome. Nonetheless, earlier research showed that there is heterogeneity within the subtypes, which makes predictions of outcome based on subtype less reliable than they might otherwise be.

"By understanding the underlying mechanisms that conribute to tumor heterogeneity and metastatic progression, including the epithelial to mesenchymal transition, we hope to be better able to guide the development of prognostic and therapeutic strategies to improve patient care," says Ursini-Siegel.


'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Related medicine news :

1. Genetics and lifestyle have a strong impact on biomarkers for inflammation and cancer
2. Search for biomarkers aimed at improving treatment of painful bladder condition
3. Biomarkers Aim to Help Predict Heart Disease Risk, From the August 2014 Harvard Women's Health Watch
4. Allegheny Health Network Team Develops Biomarker for Early Detection of Esophageal Cancer
5. Monoamine oxidase A: Biomarker for postpartum depression
6. Researchers identify potential biomarker for AD
7. Three Eyes Are Better Than One: Multidimensional Approach Provides More Complete Picture of Possible Predictive Biomarkers
8. Pseudogenes may provide clearer understanding of biomarkers
9. Biomarker predicts effectiveness of brain cancer treatment
10. Biomarkers predict long-term outcomes in juvenile idiopathic arthritis
11. Potential anti-TNF response biomarker identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology: